OpenAI’s Eye-Popping Raise & Hair Today, Hair Forever 4/1/26

1 Apr 2026 · 35 min · 17 chapters

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

This episode of CNBC’s Squawk Pod covers markets and geopolitics, then pivots to two tech/health investment stories. Topic: ARK Invest adding OpenAI to public ETFs after a $122B funding round valuing OpenAI above $850B; plus “hair today, hair forever” with Veridermix’s oral pattern-hair-loss drug in clinical trials.

Guests

Kathy Wood, CEO/CIO of ARK Invest; Dr. Reid Waldman, CEO of Veridermix (board-certified dermatologist).

Key claims

Wood says adding OpenAI to ARK ETFs is a “bridge” from private to public markets and argues AI could be the biggest innovation catalyst; she cites ChatGPT developer growth and expects AI-driven entrepreneurship. Waldman claims their compound VDPHL01 provides steady, durable follicle exposure versus minoxidil’s short-lived peaks, aiming to reduce side effects.

Notable examples

ARK Venture Fund holding OpenAI (up 65%); Veridermix priced at $17, rising to about $63; phase 3 includes the first oral phase 3 trial for female pattern hair loss.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Chapters

Tap a time to open that second in VO

Market Overview and Economic Outlook

0:00 to 0:54

The hosts discuss the current state of the stock market and economic indicators.

“Introducing the Total Solutions Advantage only from Comcast Business.”

Market Overview and Economic Outlook

2:20 to 3:45

The hosts discuss the current state of the stock market and economic indicators.

“Welcome to Squawk Box right here on CNBC.”

Nike's Sales Challenges

3:45 to 5:40

Discussion on Nike's recent sales decline and strategic changes.

“From what was all the things that were said yesterday from both the president and from Iran seem to be.”

Gulf Region Tensions and Military Strategies

5:40 to 7:55

Analysis of the geopolitical situation in the Gulf and potential military actions.

“Nike's in the midst of a turnaround effort led by CEO Elliott Hill.”

Future of U.S.-Iran Relations

7:55 to 14:00

Speculation on the future of U.S. involvement in Iran and regional stability.

“to join a military coalition to reopen the Strait of Hormuz by force.”

SpaceX's IPO Plans and Retail Allocations

14:00 to 15:36

Discussion on SpaceX's expected IPO and retail share allocations.

“All right, Dan, obviously a lot happening there.”

OpenAI's Record Funding Round

15:36 to 17:04

Overview of OpenAI's $122 billion funding round and its implications.

“They each agreed to invest tens of billions of dollars.”

Introducing the Toupee Challenge

17:04 to 18:50

Hosts discuss a fun segment involving hair and a new product for baldness.

“Coming up on Squawk Pod, ARK invests Kathy Wood.”

The Future of OpenAI and Tech Innovation

19:28 to 22:20

Kathy Wood discusses OpenAI's democratization and the AI revolution.

“OpenAI will go into several of Cathie Wood's other funds as well.”

AI's Impact on Job Creation and Money Management

22:20 to 26:06

Exploration of AI's role in job markets and asset management.

“You've got some futuristic, very bullish prognostications, as you usually do for technology.”
Show all 17 chapters

Current Trends in Cryptocurrency

26:06 to 28:01

Discussion on the state of Bitcoin and the impact of quantum technology.

“Do you anticipate that that will change over time?”

Bitcoin's Institutionalization and Quantum Risks

28:01 to 29:28

Learn about the emerging institutional interest in Bitcoin and the potential risks posed by quantum technology.

“Many people are focused on quantum as a risk to Bitcoin.”

Introduction to Hair Regrowth Biopharma

29:32 to 29:53

Discover the upcoming segment featuring the CEO of a hair regrowth company.

“The entire time I've had hair, this is hair.”

CEO Interview: Dr. Reed Waldman of Vera Dermix

31:28 to 32:41

Engage with Dr. Waldman as he discusses hair loss treatments, their effectiveness, and the company’s IPO.

“Wait, I think I need to go to superpower.”

Efficacy and Safety of Hair Loss Treatments

32:41 to 37:28

Explore the clinical trial data and safety profiles of new oral hair loss treatments.

“Or in the ladies, it's just, you see it, it's pattern baldness, which is, is it the biggest cosmetic market in the world to address?”

Discussion on Hair Loss Treatments and Competitors

37:28 to 38:44

Delve into the competitive landscape for hair loss treatments and the unique approach of Vera Dermix.

“No, it was studied in a phase two trial in the 90s.”

Discussion on Hair Loss Treatments and Competitors

39:11 to 40:47

Delve into the competitive landscape for hair loss treatments and the unique approach of Vera Dermix.

“Ask your doctor about ZepBound, Terzepatite, the first and only FDA-approved prescription medicine for moderate to severe obstructive sleep apnea, OSA, and adults with obesity.”
Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:00Introducing the Total Solutions Advantage only from Comcast Business. It's the largest, fastest fiber-powered network for small business. Gig speeds with equipment and security included, and a five-year price lock. No one does business like Comcast Business. Switch today. Get started for$60 a month for 12 months when you add an advanced solution to a qualifying internet package. Limited time offer. Restrictions apply. New customers only. Requires 300 megabits per second internet, security edge, and additional qualifying service. One-year agreement, paperless billing, and auto pay with bank account required.

0:29Taxes and fees extra. Your data lives everywhere. On-prem, in the cloud, across apps. Bring it all together with EverPure, the platform that acts like a living system, delivering the latest in data performance, security, and innovation without ever slowing you down. Sophisticated enough to anticipate your ever-changing data needs,

0:47Cathie Wood:yet simple enough to feel like second nature. Tame your data chaos with EverPure and make storage and data management the simplest part of your business. Visit everpuredata.com to learn more. Bring in show music, please.

1:27Cathie Wood:OpenAI will soon be included in ARK Invest funds. We're continuing to serve as a bridge from the private markets into the public markets, given what we do, which is focus exclusively on technologically enabled innovation. Then hair today, hair tomorrow. The stunning stock story of hair loss treatment startup Veridermix, CEO Reid Waldman. We haven't had an approval for hair loss in nearly 30 years. Plus the rest of today's news that got us squawking. From Nike's sales fall to SpaceX's IPO to the complicated and still clogged key oil path, the Strait of Hormuz. Our Dan Murphy reports from Dubai.

2:07It's pretty clear now that not all of Washington's Gulf allies want the war to end just yet. It's Wednesday, April 1st. No fooling here. Squawk Pod begins right now. Stand back to you by in three, two, one. Cue it, please. Good morning, everybody. Welcome to Squawk Box right here on CNBC. We're live from the Nasdaq market site in Times Square. I'm Becky Quick, along with Joe Kernan. Andrew is off today. Got a lot going on for the first day of the month, first day of the quarter. All three of the major averages coming off their best day since last May. But the averages still saw losses for the quarter and for the month.

2:47In fact, for the month, it was the worst performance in over a year. S &P 500 was down about 4.6 % for the quarter. The Nasdaq was down more than 7 % and the Dow down by about 3.6%. But if you look at all of them, the Nasdaq is still in correction territory, but barely. The Dow pulled out of that and the S &P is much less off of its all-time high too. I think it's only down by about 6.7 % from the all-time high. Yeah, from those, because that's, what is that, since the beginning of the year, I guess. That's not when the highs were. Right. Because it looks It's like they've all come out of correction.

3:20Yeah, NASDAQ is like 10.1 % or something. NASDAQ was, that number yesterday was. Pretty incredible. What was it, 3.7 %? You don't see the raw number too often. 800 points, basically, up 800. But it was only, it was 3.5%. But that was a big snapback. The expectation that the war could be ending very quickly. We'll see. From what was all the things that were said yesterday from both the president and from Iran seem to be. I mean, the question is what happens to the straight of the four moves. You see the spread reopens. You see the spread, too? From the WTA. We'll look at that in a second because it I mean, it's it narrowed significantly.

4:07Significantly. It had been widening out. Both came down. The 10 year right now is at four twenty eight. The two years at three seventy six. If you check out energy prices this morning, you will see that WTI and Brent have both come down pretty substantially. WTI is sitting right at$100. Oh, yeah. It's only$120, wasn't it? Yeah. Brent crude is sitting at$103.73. So, yeah, it had been, I want to say it was even$10 spread at one point. Yeah, I think it was more than that, actually. Yeah. Watching this very closely. Yeah, that's what I was doing. I was looking, trying to get an exact high on Nike, and I've complained about Nike for a while.

4:43I won't get into it, but I don't buy Nike products anymore after the whole Colin Kaepernick. It just, I don't need it. It's been years for you. Yeah, it's been years for you. I won't buy any, and I haven't, but anyway, that happens. People don't think that it happens when cultural things, but it was$179 stock. So the 60, what is the market cap now? And what the market cap will be after today, it's about 60 billion right now. So it was at least three times that. So at one point it was 200 billion. Biggest clothing in the world. And it's just been, well, there it is. It speaks for itself. Company warning that sales will fall for the rest of the calendar year, led by an expected 20 percent decline in the key China market in the current quarter.

5:41Nike's in the midst of a turnaround effort led by CEO Elliott Hill. It beat top and bottom line estimates in its latest quarter. But the company's CFO said Nike expects sales in the current period to drop two to four percent versus a one point nine percent gain expected by analysts. also flagged potential business volatility related to the war in the Middle East. And it's in my mind, the woke you go broke portfolio. Although they've had a lot of other problems along with that. All of them have. Disney, you can't blame everything on Disney. Target, you can't blame everything. I just do. Well, Nike had the big problem where they were trying to go direct to consumers, big changes during COVID.

6:22But yeah, it all adds up to a lot. They thought they'd be in a better place than they are right now after the change. It was the, you know... China's the big problem. Nothing gets cold and camera. I don't like socks that have cops portrayed as pigs. I don't like kneeling for the... It was all that stuff. And Nike just said, you know what? We're going to go with what seems to be in vogue right now at the time. And it turned off a lot of people. But they've also had trouble with China. And that's a huge part of the problem that they're talking about right now. Channels and all that. A million problems at Nike.

6:53There's a lot of U.S. brands that have struggled in China over the last several years with the tensions that have built up there, too. Also tonight, the White House says that President Trump will address the nation on the war in Iran that is anticipated at 9 p.m. Eastern time tonight. Just in the last several hours, Iran launched several missiles at Qatar. And CNBC's Dan Murphy joins us right now from Dubai. He's got the latest in the region. How are things feeling there? Does it feel like there could be de-escalation coming, Dan? Becky, good morning. Well, that's the great hope of this hour. And this relief rally that we're seeing in the markets also comes after President Trump said the US could be out of Iran within two to three weeks.

7:33But in the same breath, the president also pushing back on any responsibility for the closed straight of Hormuz. And when asked about the straight overnight, President Trump said, we're not going to have anything to do with that. Of course, remember, Trump had threatened allies unwilling to help reopen it, telling them on social media that they would have to start learning how to fight for themselves. And then, of course, this morning, a fresh headline, the United Arab Emirates now preparing to join a military coalition to reopen the Strait of Hormuz by force. That's according to the Wall Street Journal, citing Arab officials.

8:07It would, of course, make the UAE the first Gulf state to become a combatant in this war. Now, the UAE is maintaining its defensive posture and reserving its right to self-defense, it says. But behind the scenes, it's also lobbying for a UN Security Council resolution to authorize any action. And a vote is actually expected on this as soon as Thursday. The foreign ministry telling CNBC this morning that the UAE is ready to support international efforts aimed at safeguarding maritime security, but any engagement would need the support of international partners and be in line with international law.

8:44What's also interesting is that the AdNoc CEO, Dr. Sultan al-Jabba, also went one step further, saying the world must act together and UNSC Resolution 2817 must be upheld to ensure free navigation through the Strait of Hormuz. So it's pretty clear now that not all of Washington's Gulf allies want the war to end just yet. Senior officials here have also said they want Trump to continue to press ahead with the bombing, concerned perhaps that an early exit could leave their countries exposed to future Iranian attacks. Becky? Yeah, Dan, that certainly seems over the last 24 hours to have been the shift here, that the U.S.

9:22prerogative is no longer to open the Strait of Hormuz. I don't know how much of this is posturing, how much of this is frustration with NATO allies who have said that they would not come in and help right now, but potentially help once the war has died down, once tensions have died down. A head fake for an Easter raid or something. Potentially. There's another aircraft carrier that's on its way from California, should be arriving in the next couple of weeks. And the question is, why do you build up forces if you are talking about pulling out at the same time, unless that's a detente situation?

9:53It sounds, though, that there's an awful lot of concern about the Gulf states there being left to fend for themselves. Exactly. And that's the key risk at this point as well. Of course, all eyes are going to be on President Trump's address to the nation later this evening. It's going to happen at 5 a.m. here in the Gulf and, of course, this evening in the United States. The question of exactly which direction the president goes is being very closely watched in these capitals. Of course, we still don't know if the president is going to signal an off-ramp here of sorts and decide to declare mission accomplished or if he's going to double down and, in fact, push ahead with these threats that he has been leveling to put boots on the ground inside Iran and take the oil, to use the phrase that he has put out on social media in the last couple of hours.

10:45So the Gulf capitals are really on edge. There's really no sense of which direction this is going. And of course, the big question also being asked now that we do have these signals that an off-ramp is coming is, is the region necessarily better off, safer and wealthier as a result of this war? And Of course, the administration would argue yes, but you also get the sense that citizens here and, of course, leaders here could easily argue otherwise, given the fact that the president could perhaps be on the cusp of pulling out and leaving the region with not just the Strait of Hormuz problem to deal with, but also a very unknown leadership regime inside Iran and, of course, the ongoing threat of attacks on this part of the world as well.

11:25Dan, so I was watching a report yesterday showing that, you know, Iran is a huge, It's what, three times the size of Iraq or something. It's a huge country. Looking at different vulnerable areas where if you wanted to seize that uranium, where you wouldn't be facing a million man army, it could almost. I just wonder what is being presented to the president in terms of special forces. He mentioned something that called the discombobulator, which was used in Venezuela. I'm wondering whether that's on the table at this point still. And I guess we just have to keep it in the back of our mind that we don't know what is in the planning stages.

12:07And we have no idea about of what could be possible. But it's hard to defend the country so big. There are places that that are, I guess, are the CIA and the Department of War would be considering for some type of operation like that. And I think we may know more about the location of the uranium pounds of the uranium. I think, you know, Israel had. What do you do with it? Put it in a backpack. I don't know what. I don't want to carry it around. But you say, how do you find it? Bring a Geiger counter. Yeah. But then what do you do with it? Do you hear anything like that, Dan? I mean, there are it is a huge country.

12:44What? It's a third of the size of the of the United States, I think. Yeah. Right. Iran is a population of about 90 million. This is a huge country with quite a lot of power as well militarily and of course through its own proxies despite the fact that we have seen really significant work underway by the americans and the israelis to degrade that threat i think the other question is what will it take for the white house this administration this president to actually be satisfied that iran has been degraded enough decapitated enough if you will in order to move forward here and of course the president has spent a lot of time talking about how we have seen regime change inside Iran.

13:24I think the question is regime change to what? Still a lot of uncertainty inside the country and outside the country as well about exactly what the region is going to be dealing with in the future. And of course, the risk of attacks, particularly being leveled towards the Gulf states, has not diminished in the slightest. We've also seen a ramp up of attacks in the last 24 hours here. So look, the question of what happens next, still very unknown at this stage. Markets are really taking this in their stride. Oil prices cooling off, risk assets rallying up off the back of this in Europe and in Asia.

13:59But of course, all eyes on the president's address to see exactly what he is going to do next. All right, Dan, obviously a lot happening there. And we appreciate your perspective as always. Dan Murphy, thank you. SpaceX reportedly now partnering with more than 20 banks on what's expected to be a blockbuster IPO. Digstiver, maybe. Reuters says Morgan Stanley, Goldman Sachs, J.P. Morgan, Bank of America and Citigroup are serving as lead banks managing the deal, which is codenamed Project Apex. It could see SpaceX make its public debut in June, as early as June, among other firms reportedly participating.

14:39Allen & Company, Deutsche Bank, Raymond James, UBS, and Wells Fargo might be easier to figure out who's not participating. But Elon Musk also said something about retail allocations being larger than normal instead of just all the rich, you know. That wouldn't surprise me. I know. But he's kind of. In the old days, if you got, if an office, like a Merrill Lynch office, got like 100 shares of a hot IPO and then you'd give it to your friends and family. Your biggest client. Yeah. Yeah, and that's why, you know, when they did it a little bit differently, some of the tech companies. Yeah, like Google, some of them wanted to do it was the reverse.

15:18It was a little bit different, yeah, the Dutch auction. The Dutch auction, right, right. OpenAI now announcing it closed a$122 billion funding round, valuing the company at more than$850 billion. Amazon, NVIDIA, and SoftBank anchored that round. They each agreed to invest tens of billions of dollars. That's one of the biggest fundraisings that we've seen as well. Anticipation now building for an IPO for this company from Sam Altman's OpenAI, which has been curbing spending plans and features in recent months as it looks to rein in costs. The company says its shares will soon be included in several ETFs offered by ARK Invest.

16:00We're going to be speaking to Kathy Wood, that firm's CEO. You know what else we have coming up? No. So you need to, if you're not ready for this, you need to read this. Because you're going to be, we're going to make you famous again. We're going to bring, we're going to haul out the toupee challenge. You know how long I've been dealing with toupee. We're going to speak with the CEO of a company called Veridermix. He's a board certified dermatologist. Think of sustained release minoxidil pills that actually work. Think about what that would do for pattern baldness. And it might replace my propitia, and then I could stop taking my testosterone down to zero.

16:45You said that I get to do the challenge again. Are we bringing out a... No, we're just going to show how long that hair has been a subject on this. This stock came public at 17, just a month or two ago, and it's at 60 or something. Wow. Because of the potential for curing pattern baldness in men and women. I think that's interesting. It actually is interesting. He'll be here. He's on set. I beg to have him on. Cheese will be next. Coming up on Squawk Pod, ARK invests Kathy Wood.

17:17Cathie Wood:The beloved tech investor has some advice for the community. Follow the developers and become one now that you can. This is all about natural language programming. That conversation's up next.

17:31At Oppenheimer, we're proven because we're grounded in discipline. For 145 years, we've been building and protecting wealth through every market cycle. With precision, clarity, and the courage to think boldly beyond the moment. This is what market-tested legacy looks like. For this generation and the next. Put the power of Oppenheimer Thinking to work for you. Wealth Management, Capital Markets, Investment Banking. This NBA Playoffs with FanDuel. You're not just watching the playoffs, you're a part of them. Steve's got the phone, opens FanDuel, and he's going for threes! Be a part of the action on FanDuel.

18:12All customers get a profit boost every NBA playoff game day. 21 plus and present in select states. Opt-in required. Bonus issued is non-withdrawable profit boost tokens. Restrictions apply, including any token expiration and max wager amount. See full terms at FanDuel.com slash sportsbook. Gambling problem? Call 1-800-GAMBLER or 1-800-MY-RESET. With Uber's new women preferences, women riders can request a woman driver whenever they want. Like Amy, who's traveling solo in a city she's never been to before. Or Danielle, who works night shifts at the hospital. Or Kelly and Jana, who were way overdue for a night out.

18:50Because sometimes comfort comes from having another woman with you. Request women drivers with woman preferences on Uber. Learn more on the Uber app.

19:03This is Squawk Pod. I'm Becky. Q. You are watching Squawk Box right here on CNBC. I'm Becky Quick along with Joe Kernan. Arc Invest participated in OpenAI's record-breaking$122 billion funding round. The company now has a valuation of$850 billion. OpenAI is one of the biggest components in the ARK Venture Fund, along with SpaceX, Anthropic, and other big-name private companies. The fund is up 65 % in a year. OpenAI will go into several of Cathie Wood's other funds as well. Cathie Wood, ARK Invest CEO and CIO, is with us this morning. Cathie, it's good to have you on. And I don't know whether to say congrats or what, but this is this this helps allow people that typically would not be able to invest in OpenAI the opportunity to do that.

20:04So I don't know whether you call it a partial democratization of it, but it's baby steps.

20:09Cathie Wood:Yes. Hi, Joe. Thank you. Yes. Actually, ARKVX, which is our venture fund, was the first place we offered OpenAI. It now is up to number two in the portfolio. But the news today is that, yes, in our ETFs, ARKK, ARKW and ARKF, we've added OpenAI. And so, yes, we're continuing to serve as a bridge from the private markets into the public markets, given what we do, which is focus exclusively on technologically enabled innovation. I mean, they're staying private longer. Some of them don't come private at all. So this is this is a model that could be used. And I have a feeling there's going to be a lot of technological advancements over the next five or 10 years where this would definitely be helpful for for average people.

21:04Cathie Wood:Absolutely. I mean, we do believe, and this is not an exaggeration, we do believe we're in a technology revolution and AI is the biggest catalyst for innovation in history. Can you delineate why OpenAI is the most attractive? I mean, you had choices, I guess, didn't you? Well, in terms of the ETFs, it was really OpenAI who wanted to partner with us and perhaps some others to help this democratization movement. What is the number one question we used to get from our clients? It was, why don't we have access to these sorts of opportunities? They used to go to accredited investors only. Really, you had to have, I think, a million dollars in net worth and$250 ,000 in income per year.

21:56Cathie Wood:And so that seemed a little un-American to us. And I think OpenAI agreed. We can hold up to 15 percent in illiquid stocks in ETFs. Of course, ETFs trade all day long. So we are well under that threshold at roughly 3 percent in these three funds. And are we at a tipping point yet for AI? You've got some futuristic, very bullish prognostications, as you usually do for technology. What will it mean? And will anyone have a job, Kathy? be? Well, first, technology historically has been a net job creator. But you're right, Joe. We're seeing entry level jobs slow down quite significantly in terms of their growth in some in some countries contracting.

22:52Cathie Wood:And yet I think that might be a blessing in disguise. We're seeing the big problem, obviously, entry level in the 16 to 24 year old cohort where the unemployment rate is 9.5 % right now. But we think that there's going to be an entrepreneurial explosion. And what I tell young people, go start a business with ChatGBT or any of the other, just experiment, but just go for it. I mean, ChatGBT, I think, has 2 million developers now, and that's up fivefold or sixfold in the last few months as they've released new products. So, you know, follow the developers and become one now that you can. This is all about natural language programming.

23:40And we're over the hump now in agentic AI, you think. Here they come.

23:47Cathie Wood:Well, I see it at ARC. I see our chief futurist, Brett Winton. He probably has four or five agents working for him at all times doing projects that he just looks in on. And, you know, it's astonishing. We started at$20 per month subscription. Now he and the heavy users are up to$200 per month. But last week we even had a discussion about, hey, maybe, you know, maybe we need$2 ,000 per month worth of tokens so that we can send these agents out and, and do the reasoning to help me get through these projects. It's pretty astonishing what's going on. Kathy, don't you think that AI would be pretty good at managing people's money, maybe even better than humans in not a very long period of time, I would think?

24:42I don't know if you want to get this moving too quickly for anyone that's in the money management business.

Read the full transcript

24:48Cathie Wood:Well, I think what has happened in the asset management business is a shift towards benchmark sensitivity. And so I think AI can do that. Yes. I think that the shift towards, hey, let's mimic this S &P 500 or NASDAQ and, you know, a little bit more here, a little bit less there in terms of benchmark sensitivity. I think AI will be very good at doing that, just like it does a great job at passive. I mean, the more futuristic you get, meaning you have to do original research, try and figure out how all of these technologies are evolving, the costs are collapsing, how quickly they're going to scale across sectors and industries, that probably will take a little more time.

25:41Cathie Wood:And that's why I founded ARC. I feel like that part of our business has, it disappeared, especially when M &A activity disappeared under the last FTC. You know, there was no strategic price discovery. And this idea that investing in the future was exotic is something we were trying to capitalize on. Hey, Kathy, historically, ARK has underperformed the NASDAQ 100. Do you anticipate that that will change over time? Yes, I think what you've seen over the last, well, what you've seen over there, certainly the last five years, was extreme concentration into the benchmarks. Again, the safe way, tried and true.

26:31Cathie Wood:Yeah, actually, we're compared more to the mid-cap growth indexes. And I think even Morningstar has us within the top 10 in the last 10 years. So from that point of view, I think we've done quite well. Double digit returns, 12, 13 percent since inception, even though there was a drought there for a while. I think we're coming out of that drought. And I think this technology revolution, many more people are beginning to understand because they're using AI, they're using chat GPT. And we have focused our research around AI, robotics, energy storage, blockchain technology, and multi-omic sequencing, all of which are converging.

27:18Cathie Wood:And so we've set up our research team very differently from other research teams in the asset management world. We had a crypto winner. It's ruined something. If so, is it you think it's like December 15th or like February 31st? What do you think? Where are we? Yes, well, Bitcoin and we follow all kinds of crypto assets, Bitcoin being the leader. It has been in a bit of a winter. I think it all started with risk off and complicated by the flash crash last October. I think that's washed through the system now. We do have we or I shouldn't say we. Many people are focused on quantum as a risk to Bitcoin.

28:09Cathie Wood:And I'm not going to say we're dismissing it, but we've done a lot of research on this. And we think that quantum resistant wallets are an important part of the answer. And I think I think we're in a bottoming out phase now, Joe. And the halvings coming up, I guess that always it almost goes in cycles. Is it four year cycles? It dropped Bitcoin, pulled back 80 percent. It's over 50 at some point, isn't it? So is it going to pull back less in these periods at this point or nobody knows? Yes. Yes. I think what we're seeing now is the institutionalization of this new asset class that has a very low correlation with other asset classes.

28:54Cathie Wood:So believe it or not, in the in the Bitcoin community, down 50 percent, if that's as far as it goes, they'll consider that a real victory because you're right. The 85, 95 percent collapses associated with a very new technology that's done. This is a proven technology. It's a proven monetary system and it's a new asset class. Right. Could be something really risky like Nike stock at 180. Now it's 40. All right, Kathy, we appreciate your time. Thank you. Thank you, Joe. Thank you. Still to come on Squawk Pod. Go ahead. Joe's hair, it's real. The entire time I've had hair, this is hair. But many 80-ish million Americans rely on hair loss treatments to keep their locks flowing.

29:46CEO of Hair Regrowth Biopharma, Veridermix, is up next. At Venture Global, we think about what can be done, not what's usually done. Through innovation, Venture Global is not only building some of the largest energy facilities in the world, right here in the United States, but delivering American energy at a fraction of the cost and a fraction of the time. So while others are busy talking, we're busy building. That's Venture Global. That's unstoppable energy. This NBA playoffs with FanDuel. You're not just watching the playoffs. You're a part of them. Steve's got the phone, opens FanDuel, and he's going for threes.

30:32Be a part of the action on FanDuel. All customers get a profit boost every NBA playoff game day. 21 plus and present in select states. Opt-in required. Bonus issued is non-withdrawable profit boost tokens. Restrictions apply, including any token expiration and max wager amount. See full terms at fanduel.com slash sportsbook. Gambling problem? Call 1-800-GAMBLER or 1-800-MY-RESET. With Share My Trip from Uber, you can send your live trip location to the ones who matter most. Like Dan and Hannah, who always wait up to make sure their daughter gets back to her college dorm room. or Tiffany who's running late as usual and her friends are tracking her trip to make sure she's actually on her way.

31:07Look, she's right there. She's three minutes away. Or Sam who never goes anywhere without her roommate knowing exactly where she is. Some journeys are meant to be shared. Share your ride in real time with Share My Trip on Uber. One more way Uber is putting safety at every turn. Learn more on the Uber app.

31:27You're listening to Squawk Pod from CNBC. Wait, I think I need to go to superpower. That's not working. Hold on. And this sound you hear is a leaf blower in a television studio. We've all been doing this show a long time. Back in 2015, our Joe Kernan voluntarily allowed Becky Quick to use a leaf blower to prove his hair was firmly connected to his scalp. All natural growth. This was an effort to put to bed rumors and speculation to the contrary. But we can't just leave it there. The name of this company at BioPharma is called Vera Dermix. It came public. He's here. Let's talk to him. You can answer all our questions.

32:08It's up 67 % since the company's IPO in early February, thanks to investor appetite for pattern hair loss treatments. Joining us now is Dr. Reed Waldman, CEO of Vera Dermix. It was priced at what? $17 when we went out. Opened where? About$34. At 34 now, it's at? 63. And it's a small market cap still, but it's a mid cap, what,$2.5 billion or so. You've got your main compound is called VDPHL01. And PHL is pattern hair loss, baldness. Or in the ladies, it's just, you see it, it's pattern baldness, which is, is it the biggest cosmetic market in the world to address? Yeah, so this is the single most prevalent chronic dermatologic condition in America.

33:00Affects 80 million people. That is 10 times more than psoriasis. Psoriasis has more than a dozen blockbuster drugs. We haven't had an approval for hair loss in nearly 30 years. And this is like minoxidil or Rogaine. But when you do that, you rub it on, it's good. Or even if you take it as a pill, what is it good for like an hour? Or it peaks at four hours, then it's gone. And that can't do anything to the follicles, or it's not that effective. Exactly. So same molecule as Rogaine, but a fundamentally different medicine in that we give consistent and durable exposures at the follicle throughout the day to promote hair growth.

33:37And we keep those levels steady to try and reduce side effects. So phase two and phase three, it's not, you can't get this yet, right? And it would be a pill, but what kind of, those are, phase two is safety, right? But can you see efficacy in phase three? What kind of things are you allowed to talk about? Yes, we have phase two efficacy data. And in phase two, we demonstrated the drug is fast. People get visible results as early as two months, that it was consistent. The vast majority of people in our trial got clinically meaningful hair growth, that it was intense using a quantifiable and objective metric.

34:10We saw hair count changes that are out of proportion to what's been seen previously while having good tolerability. We now have three ongoing phase three trials, including the first ever phase three trial for an oral treatment for female pattern hair loss. I was kidding. It's been how long is the show? We did our 30 year anniversary. When did we do the toupee challenge? Because the entire time had to be 12, 14 years ago, maybe the entire time I've had hair. This is hair. This is my hair. I always say it's real human. No, it's my real human hair. Run that video. We have done the toupee challenge where Becky got a leaf blower and because we had to finally answer the critics.

34:51And I still send that to people because I still get the toupee stuff. I get the toupee stuff. I get it. So, you know, this gave me an excuse to run it again that you were you like doing that. And you were you did. You liked pointing that dangerous. I still have a mark on my leg from where you shot me with it. With a paintball gun. At close range. So, doctor, I want to know about competition and other things. And I have, you know, just to shut these people up, I have copped to Propecia, which is finasteride, which has some side effects and doses can be a problem. I guess Rogaine can be a problem, too, right?

35:30Cardiac, and this is a low enough dose. So, exactly. One of the main reasons that people don't treat their hair loss is concern about side effects, in particular with Propecia that is associated with erectile dysfunction. Oh, my God. You didn't have to say that. Right. So if you take Propecia, you may be taking some other drugs, too. Yeah. And so here we have a non-hormonal medication. So it's not anticipated to cause things like erectile dysfunction or decrease. Dynomastis something or other. None of that. What are the potential side effects? And the other question is, does it make hair grow everywhere on your body?

36:03Yeah. So in phase three, we'll characterize the safety profile. but from a hair everywhere, what we can tell you is we do not anticipate that to be a meaningful tolerability challenge. Are there other issues that could be potential side effects? That's really where in phase three we've got 1 ,500 people we'll evaluate in, which gives us the ability to detect anything that would be anticipated to occur in about 0.2%. Are you a one-trick pony that you got other things going on at this company? Right now we're laser-focused on growing hair. This is a tremendously large problem, and to be excellent at solving for a tremendously large problem, and we want to stay focused.

36:37Who are your competitors? There's other companies doing very similar things, or are they all using minoxidil? So it's interesting. We are the only oral treatment that is in clinical trials in the United States, and we know that patients prefer an oral treatment because very few people want to put something messy, cumbersome in their scalp twice a day for the rest of their lives. In defense of Propecia, it's a prostate. It is. It's very effective. I mean, I think I have, like, zero whenever I get the, like, a PSA thing or what, but it is a little ironic when I'm watching commercials saying, get super T to get your testosterone high.

37:13And I'm bringing mine to zero, basically. Well, and of course, and so not only is there, right, this impact on testosterone in men, but we don't see efficacy in women for Propecia because testosterone doesn't drive their hair loss. So they can't benefit from finasteride. No, it was studied in a phase two trial in the 90s. It did not show benefit. And that's one of the reasons we're running this phase three trial for females to get that first simple pill approved in the female population potentially. What's up? Well, just oral minoxidil in general can be used to treat high blood pressure because high blood pressure adds to the work.

37:47That's what it was for initially, right? Exactly. So the minoxidil that exists today is fundamentally a blood pressure medication. You take it, it spikes quickly in your plasma. Within two hours, majority is gone. Four hours, almost all of it's gone. Those spikes drive cardiac effects, and they're not needed for hair. So we're giving these consistent and durable exposures throughout the day. But it can lead to weight gain, fast heartbeat, and chest pain. And higher because of those spikes. You think your doses are low enough. And that's why we give these low doses throughout the day to reduce the risk of those side effects by eliminating those peaks.

38:19Right. The unwanted hair would be hair on your back, hair on your palm. I mean, these are certain things that, right? Things you worry about. Doctor, that was a fun segment. But it is a serious segment. And hopefully I have laid the people on TV get the toupee stuff all the time. It's not a toupee. Thank you, Dr. Waldman. Thank you for having me. I appreciate it. Okay. We'll see what happens. And that is Squawk Pod for today, this Wednesday. Thanks, as always, for listening. Squawk Box is hosted by Joe Kernan, Becky Quick, and Andrew Ross Sorkin. Tune in weekday mornings on CNBC at 6 Eastern to get the smartest takes and analysis from our TV show right into your ears.

39:04You know what to do. Follow Squawk Pod wherever you like to get your podcasts. We'll meet you right back here tomorrow. We are clear. Thanks, guys. Thank you so much.

39:26Ask your doctor about ZepBound, Terzepatite, the first and only FDA-approved prescription medicine for moderate to severe obstructive sleep apnea, OSA, and adults with obesity. ZepBound is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with moderate to severe obstructive sleep apnea, OSA, and obesity to improve their OSA. ZepBound is approved as a 2.5, 5, 7.5, 10, 12.5, or 15 milligram injection. Z-Bound contains terzepatide and should not be used with other terzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Z-Bound is safe and effective for use in children.

40:07Don't share needles or pins or reuse needles. Don't take if allergic to it or if you or someone in your family had medullary thyroid cancer or if you've had multiple endocrine neoplasia syndrome type 2. Tell your doctor if you get a lump or swelling in your neck. Stop Z-Bound and call your doctor if you have severe stomach pain or a serious allergic reaction. Severe side effects may include inflamed pancreas or gallbladder problems. Tell your doctor if you experience vision changes before scheduled procedures with anesthesia, if you're nursing, pregnant, plan to be, or taking birth control pills.

40:36Taking ZipBound with a sulfonylurea or insulin may cause low blood sugar. Side effects include nausea, diarrhea, and vomiting, which can cause dehydration and worsen kidney problems. Talk to your doctor. Call 1-800-545-5979 or visit ZipBound.lily.com.

From the publisher

OpenAI has closed a $122 billion funding round, bringing its valuation to $852 billion. Investor Cathie Wood discusses her bets on AI and the future of tech investing. Nike reported a struggle in the Chinese market for its latest quarter, and CNBC’s Dan Murphy reports on the latest in the Middle East. Plus, shares of biopharma company Veradermics are up well over 65% since its IPO in February, all thanks to investor appetite for pattern hair loss treatments. CEO and board-certified dermatologist Dr. Reid Waldman discusses the market, the audience, and the innovation in hair care. 

 

Dan Murphy - 07:03

Cathie Wood - 19:14

Dr. Reid Waldman - 32:01

 

In this episode:

Dan Murphy, @dan_murphy

Cathie Wood, @CathieDWood

Becky Quick, @BeckyQuick

Joe Kernen, @JoeSquawk

Katie Kramer, @Kramer_Katie


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from Squawk Pod

All 546 episodes
OpenAI’s Eye-Popping Raise & Hair Today, Hair Forever 4/1/26Squawk Pod · 35 min
Listen in VO